avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today that avVaa is in the final stages for completion of the Neuroskin(R) Psoriasis Relief Direct Response Television (“DRTV”) commercial.
The Neuroskin(R) Psoriasis Relief will have two cuts of the 120 second DRTV commercial with separate call to actions and toll free numbers. The reasons for two separate DRTV CTA and separate toll free number is that the media test will tell avVaa, what time is best to run the spots, what stations are working the best, what geographical areas is the Company selling into, and most importantly for avVaa, which call to action offer works best, and whether their offer was strong enough on behalf of the product and company.
Ms Farley, President/COO/Co Founder stated, “it is important to understand that doing a media test will tell us about our ROI (Return on Investment) and MER (Media Efficiency Ratio). avVaa may need to do two media tests before going into full launch. The media test month is targeted for August as August is Psoriasis Month.”
Ms Farley goes on to say, “we will be donating a certain dollar value from the sales of the DRTV commercial on the Neuroskin(R) Psoriasis Relief by avVaa to a non profit organization which is the country’s largest organization dedicated to psoriasis research and information. Our target market is the 7.5 million Americans, that’s two out of every 100 Americans that have a form of psoriasis, which there is currently no cure for.
The media test month of August should prove that the DRTV commercials were successful and avVaa World Health Care will then plan for a successful full national launch campaign.
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa’s patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the United States and globally. The Company’s secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: www.avvaa.com.